ArticleCritical care (London, England)2020

Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider.

Patrick M Honore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.